Jefferies Sets a $28 PT for enGene Holdings Inc. (ENGN)
We recently published an article titled 10 Best Low Volatility Canadian Stocks to Buy.
On January 30, Jefferies initiated coverage of enGene Holdings Inc. (NASDAQ:ENGN) with a Buy rating and a $28 price target, highlighting the company’s ongoing pivotal study in high-risk non-muscle invasive bladder cancer (NMIBC), with a key data update expected in the second half of 2026.
enGene Holdings Inc. (NASDAQ:ENGN) is positioning itself as a differentiated player in the bladder cancer treatment landscape as it advances detalimogene voraplasmid, its lead non-viral gene therapy candidate, into late-stage development. Beyond clinical momentum, enGene has strengthened its financial footing. On January 21, the company expanded its debt facility with Hercules Capital to up to $125 million, securing additional non-dilutive financing to support its planned Biologics License Application and potential U.S. commercialization. The amended agreement provides $25 million immediately to refinance existing debt and up to $100 million in additional tranches tied to clinical, regulatory, and commercial milestones. This capital structure enhances flexibility as enGene transitions from a development-stage biotech to a potential commercial-stage company in a competitive but high-need oncology market.
Founded in 1999 and headquartered in Saint-Laurent, Quebec, enGene Holdings Inc. (NASDAQ:ENGN) leverages its proprietary Dually Derivatized Chitosan (DDX) platform to develop non-viral genetic medicines targeting mucosal diseases. With pivotal data on the horizon, strengthened liquidity, and a differentiated therapeutic approach, enGene represents a high-risk, high-reward opportunity for investors seeking exposure to innovative oncology platforms with meaningful upside potential.
Disclosure: None.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The logic of "cheap yen financing" is changing! Funds are reallocating "carry trades" as Swiss franc and Swedish krona compete for the funding currency position
The appeal of yen financing has diminished, and carry traders have recently turned their attention to the franc and the krona. With the yen’s recent surge making it a less reliable investment option, currencies such as the Swedish krona and Swiss franc are becoming primary funding choices for carry trades.
Crypto Regulation Deal Collapses: 5 Altcoins to Watch Before Volatility Turns Into the Next Buying Opportunity
Jiayin Technology (JFIN.US) Holds 500 Million Cash in First Half of Year, Overseas Market Bet Becomes the Key to Breakthrough
Jiayin Financial Technology (JFIN.US) released its financial report for the first half of 2026, reporting revenue of 1.494 billion yuan, gross profit of 613 million yuan, and a gross margin of 41.03%.
Crypto prices
More
